Head-to-head · WeighScore
Gala Health vs Vitara RX
The verdict
Too close to call — both grade 86/100 (B).
Gala Health and Vitara RX land on the same WeighScore, so neither clears the other on our six graded dimensions. Vitara RX sits one line higher on the board (#7 vs #8) on the underlying tiebreak, but it's a genuine coin-flip — pick on the factors and prices that matter most to you below.
Assume any provider we list may compensate us — we may earn a commission at no cost to you. It never changes the WeighScore.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Gala Health | Vitara RX |
|---|---|---|
| WeighScore | 86/100 | 86/100 |
| Grade | B | B |
| Scorecard rank | #8 | #7 |
| Semaglutide | Not disclosed | $99/mo |
| Tirzepatide | $179/mo | $149/mo |
| Coverage | All 50 states | All 50 states |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #8 · B
Strengths
- Low compounded entry — tirzepatide $179/mo, microdose from $149, 3-month plans from $199
- Available in all 50 states
- Keeps a brand-name path open (Ozempic listed at $1,299)
- HRT and menopause care available alongside GLP-1
Where it loses points
- Compounded formulations are not FDA-approved
- Brand-name Ozempic is priced steeply at $1,299
- No oral or sublingual route offered yet
- Newer operator (Gala GLP-1 by AI Coaching Inc) with a shorter public record
Graded #7 · B
Strengths
- $99 sema / $149 tirz — bottom-quartile pricing
- Both molecules, all 50 states
- LegitScript-verified
Where it loses points
- Injection-only, no oral route
- Labs/monitoring not detailed
- Newer, thinner track record
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 31 providers, CoreAge Rx grades highest at 94/100 (A). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.